lysyl-aspartyl-glutamyl-leucine has been researched along with naphthoquinones in 1 studies
Studies (lysyl-aspartyl-glutamyl-leucine) | Trials (lysyl-aspartyl-glutamyl-leucine) | Recent Studies (post-2010) (lysyl-aspartyl-glutamyl-leucine) | Studies (naphthoquinones) | Trials (naphthoquinones) | Recent Studies (post-2010) (naphthoquinones) |
---|---|---|---|---|---|
121 | 0 | 22 | 7,110 | 149 | 2,923 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dong, Y; Lv, X; Sun, A; Tao, X; Wei, D; Xu, R; Zhang, J | 1 |
1 other study(ies) available for lysyl-aspartyl-glutamyl-leucine and naphthoquinones
Article | Year |
---|---|
TAT-IL-24-KDEL-induced apoptosis is inhibited by survivin but restored by the small molecular survivin inhibitor, YM155, in cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Gene Products, tat; Heterografts; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Interleukins; Mice; Mice, Nude; Naphthoquinones; Oligopeptides; Protein Sorting Signals; Recombinant Fusion Proteins; Survivin; Xenograft Model Antitumor Assays | 2016 |